| Literature DB >> 26819566 |
Xiaodong Mu1, Stuti Patel2, Damel Mektepbayeva3, Adel Mahjoub2, Johnny Huard1, Kurt Weiss2.
Abstract
Aldehyde dehydrogenase (ALDH) is a cancer stem cell marker. Retinoic acid has antitumor properties, including the induction of apoptosis and inhibition of proliferation. Retinal, the precursor of retinoic acid, can be oxidized to retinoic acid by dehydrogenases, including ALDH. We hypothesized that retinal could potentially be transformed to retinoic acid with higher efficiency by cancer stem cells, due to the higher ALDH activity. We previously observed that ALDH activity is greater in highly metastatic K7M2 osteosarcoma (OS) cells than in nonmetastatic K12 OS cells. We also demonstrated that ALDH activity correlates with clinical metastases in bone sarcoma patients, suggesting that ALDH may be a therapeutic target specific to cells with high metastatic potential. Our current results demonstrated that retinal preferentially affected the phenotypes of ALDH-high K7M2 cells in contrast to ALDH-low K12 cells, which could be mediated by the more efficient transformation of retinal to retinoic acid by ALDH in K7M2 cells. Retinal treatment of highly metastatic K7M2 cells decreased their proliferation, invasion capacity, and resistance to oxidative stress. Retinal altered the expression of metastasis-related genes. These observations indicate that retinal may be used to specifically target metastatic cancer stem cells in OS.Entities:
Year: 2015 PMID: 26819566 PMCID: PMC4706975 DOI: 10.1155/2015/784954
Source DB: PubMed Journal: Sarcoma ISSN: 1357-714X
Primer sequences.
| Gene | Primer sequence |
|---|---|
| GAPDH | Forward: TCCATGACAACTTTGGCATTG |
| Reverse: TCACGCCACAGCTTTCCA | |
|
| |
| Notch1 | Forward: GCCGCAAGAGGCTTGAGAT |
| Reverse: GGAGTCCTGGCATCGTTGG | |
|
| |
| Hes1 | Forward: CCAGCCAGTGTCAACACGA |
| Reverse: AATGCCGGGAGCTATCTTTCT | |
|
| |
| BMP2 | Forward: TCTTCCGGGAACAGATACAGG |
| Reverse: TGGTGTCCAATAGTCTGGTCA | |
|
| |
| Akt1 | Forward: ATGAACGACGTAGCCATTGTG |
| Reverse: TTGTAGCCAATAAAGGTGCCAT | |
|
| |
| cMyc | Forward: TGACCTAACTCGAGGAGGAGCTGGAATC |
| Reverse: AAGTTTGAGGCAGTTAAAATTATGGCTGAAGC | |
|
| |
| ALDH1 | Forward: GACAGGCTTTCCAGATTGGCTC |
| Reverse: AAGACTTTCCCACCATTGAGTGC | |
|
| |
| Klotho | Forward: CCCAAACCATCTATGAAAC |
| Reverse: CTACCGTATTCTATGCCTTC | |
Figure 1Retinal treatment of K7M2 cells decreased cell proliferation or survival. (a) and (b) The cell proliferation or survival capacity of K7M2 cells was more reduced with retinal treatment (5 µg/mL, 2 days), compared to K12 cells.
Figure 2Retinal treatment of sorted ALDH-high K7M2 cells decreased antioxidative stress capacity. After cell sorting according to ALDH activity, it showed that the K7M2-ALDH high cells were more resistant to oxidative stress (H2O2, 250 µM for 1 hr) than the K7M2-ALDH low cells, while the retinal treatment of K7M2-ALDH high cells was able to greatly decrease their resistance to oxidative stress and resulted in more cell apoptosis. “∗” indicates that ALDH-high control cells are significant different (p < 0.05) compared to ALDH-low control cells; “∗∗” indicates retinal treated ALDH-high or ALDH-low cells are significant different (p < 0.05) compared to nontreated ALDH-high or ALDH-low control cells, respectively.
Figure 3Retinal treatment of K7M2 cells modified the expression of metastasis-related genes and reduced ALDH activity. (a) RT-PCR results showed retinal treatment of K7M2 cells (1 or 5 µg/mL for 2 days) modified the expression of some key genes related with metastasis or tumorigenesis. (b) ALDH activity assay showed that retinal treatment of K7M2 cells reduced the aLDH activity of the cells.
Figure 4Retinal treatment of K7M2 cells changed migration-related cell morphological characteristics and decreased migration capacity. (a) Actin staining with phalloidin revealed that the cell morphology of K7M2 cells was modified with retinal treatment (5 µg/mL for 2 days), showing reduced presence of invadopodia. (b) In vitro invasion assay with 3D-matrigel (2.5%) revealed that K7M2 cells treated with retinal treatment (5 µg/mL for 2 days) migrated slower than nontreated K7M2 control cells.